Paradigm Biopharmaceuticals (PAR)
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company. It focuses on repurposing the drug, pentosan polysulphate sodium for the treatment of bone marrow edema. The company also develops pentosan polysulphate sodium to treat respiratory diseases including allergic asthma, allergic rhinitis and chronic obstructive pulmonary disease. Paradigm Biopharmaceuticals was founded on May 2, 2014 and is headquartered in Melbourne, Australia.
|Market Price at 23-11-2017||$0.30|
|Price to Earnings Ratio||-9.74|
|Market Capitalisation||$36.19 (million)|
|Return on Equity (ROE)||-26%|